Jazz Pharmaceuticals Reports Upbeat Trial Data


Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) reported upbeat results from a late stage clinical trial of its fibromyalgia pain treatment sodium oxybate. The stock price leaped $2.04 to $4.68.

About this Entry

This page contains a single entry by published on June 15, 2009 7:41 AM.

Satyam's Cost Saving Program To Affect Up To 10,000 Workers was the previous entry in this blog.

Cell Therapeutics May Be Added To Russell 3000 is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12